IPO registrations (S-1, F-1) · Registrants
Polaryx Therapeutics, Inc.
- SEC CIK
- 2075320 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2025-11-21, last 2026-01-27; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2026-02-02; declared effective 2026-01-29
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- WY
- Business address
- 140 EAST RIDGEWOOD AVENUE, SUITE 415, SOUTH TOWER, Paramus, NJ 07652
- Ticker
- PLYX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Polaryx Therapeutics, Inc. on the corporate pages
Offering terms
- Shares offered
- 47,343,297
- Listing
- Nasdaq under the symbol PLYX
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Polaryx Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2025-11-21 | S-1 | S-1 (registration) | Polaryx Therapeutics, Inc. | 0001213900-25-113249 ↗ |
| 2026-01-14 | S-1/A | S-1/A (amendment) | Polaryx Therapeutics, Inc. | 0001213900-26-004079 ↗ |
| 2026-01-27 | S-1/A | S-1/A (amendment) | Polaryx Therapeutics, Inc. | 0001213900-26-007973 ↗ |
| 2026-01-29 | EFFECT | EFFECT (declared effective) | Polaryx Therapeutics, Inc. | 9999999995-26-000339 ↗ |
| 2026-02-02 | 424B4 | 424B4 (final prospectus) | Polaryx Therapeutics, Inc. | 0001213900-26-010761 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | S-1/A | registration statement | 47,343,297 | - | Nasdaq PLYX | 0 | primary document; shares headline | document ↗ | ||
| 2026-02-02 | 424B4 | final prospectus | 47,343,297 | - | Nasdaq PLYX | 0 | primary document; shares headline | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Berger Mitchel | Director | 1 | 2026 | ||
| Bollinger Lisa | Officer | Chief Medical Officer | 1 | 2026 | |
| Braun III Francis A | Director | 1 | 2026 | ||
| Landis G. Michael | Director,Officer | Chief Financial Officer | 2 | 2026 | |
| Mstone Partners Healthcare Ltd | Director,TenPercentOwner | 2 | 2026 | ||
| O Andrew John | Officer | Chief Investment Officer | 1 | 2026 | |
| Ryan Charles S. | Director | 1 | 2026 | ||
| Yang Alex Keun Mo | Director,Officer,TenPercentOwner | Chief Executive Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Polaryx Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Polaryx Therapeutics, Inc | NJ | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.